NCT06920498View on ClinicalTrials.gov

A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

June 19, 2025

Study Completion Date

June 19, 2025

Conditions
Healthy Participants
Interventions
DRUG

PF-07941944

Oral formulation

DRUG

Placebo

Oral formulation

DRUG

Midazolam

Oral formulation

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06920498 - A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults. | Biotech Hunter | Biotech Hunter